U.S. FDA Accepts for Priority Review the Biologics License Application for Epcoritamab (DuoBody ®-CD3xCD20) for the Treatment of Relapsed/Refractory Large B-Cell Lymphoma

The application is supported by data from EPCORE™ NHL-1 Phase 1/2 trial evaluating the safety and preliminary efficacy of subcutaneous epcoritamab in patients with relapsed, progressive or refractory CD20+ mature B-cell non-Hodgkin ' s...
Source: Drugs.com - New Drug Applications - Category: Drugs & Pharmacology Source Type: news